AIVITA Biomedical

10:15 AM - 10:30 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
We have leveraged our expertise with stem cells to develop a broad platform targeting cancer, retinal diseases, and neurodegeneration.

In cancer, our technology isolates and propagates tumor-initiating cells responsible for metastases of cancers, to target the full patient-specific antigenic profile of that patient's tumor.

In retinal diseases, we have developed a three-dimensional retinal organoid and shown this can be implanted into animals to restore vision. This is an allogeneic product developed from validated and efficient manufacturing of human stem cells, yielding consistent, fully functioning retinal organoids.

In neurodegeneration, we have developed a non-cellular, pan-neurotrophic product to treat neurodegenerative diseases. We are targeting Alzheimer’s disease first. Pre-clinical model show that treatment leads to better overall survival of neural cells and expansion of neurites with fewer beta tubulin negative cells.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Cancer vaccine using tumor initiating cells
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided